Jul 22, 2026 08:30AM
Jul 6, 2026 08:45AM
Jun 29, 2026 09:30AM
Jun 29, 2026 09:30AM
Jun 25, 2026 09:20AM
Jun 25, 2026 09:20AM
Jun 22, 2026 09:00AM EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
Jun 11, 2026 09:02AM
Jun 11, 2026 09:00AM
Jun 9, 2026 09:01AM
Jun 9, 2026 09:00AM
Apr 6, 2026 09:20AM
Apr 6, 2026 09:20AM
Mar 31, 2026 09:20AM NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
Mar 24, 2026 09:03AM
Mar 24, 2026 09:00AM
Mar 18, 2026 08:00AM
Mar 16, 2026 11:34AM
Mar 16, 2026 11:33AM
Mar 9, 2026 11:07AM
Feb 18, 2026 09:05AM NeuroSense reports 65% death risk reduction in ALS trial
Feb 18, 2026 09:05AM
Feb 9, 2026 09:20AM
Feb 9, 2026 09:20AM
Jan 21, 2026 08:30AM
Jan 21, 2026 08:30AM
Jan 8, 2026 08:45AM
Dec 22, 2025 09:18AM NeuroSense reports favorable safety data for Alzheimer's drug PrimeC
Dec 22, 2025 09:17AM
Dec 4, 2025 07:30AM
Nov 24, 2025 09:56AM
Nov 24, 2025 09:56AM
Oct 6, 2025 09:00AM
Sep 10, 2025 02:30PM
Sep 4, 2025 08:49AM NeuroSense raises $500,000 in private placement at 40% premium
Sep 4, 2025 08:49AM
Aug 1, 2025 09:00AM
Jul 22, 2025 08:42AM
Apr 24, 2025 09:09AM
Apr 24, 2025 09:09AM
Apr 9, 2025 08:30AM
Apr 9, 2025 08:30AM NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
Apr 7, 2025 05:14PM
Apr 4, 2025 09:10AM
Mar 20, 2025 10:30AM
Mar 17, 2025 08:30AM
Jan 6, 2025 09:02AM
Jan 6, 2025 09:00AM
Dec 23, 2024 09:00AM NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
Dec 18, 2024 10:25AM

326,536 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All